MetaVia Inc.

Healthcare · Biotechnology · United States

Last price 1.19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 7.84M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 rece...